AR041346A1 - Derivados de imidazol[1,2-a]pirazinas como inhibidores de quinasas dependientes de ciclinas - Google Patents
Derivados de imidazol[1,2-a]pirazinas como inhibidores de quinasas dependientes de ciclinasInfo
- Publication number
- AR041346A1 AR041346A1 ARP030103440A ARP030103440A AR041346A1 AR 041346 A1 AR041346 A1 AR 041346A1 AR P030103440 A ARP030103440 A AR P030103440A AR P030103440 A ARP030103440 A AR P030103440A AR 041346 A1 AR041346 A1 AR 041346A1
- Authority
- AR
- Argentina
- Prior art keywords
- nr5r6
- alkyl
- heteroaryl
- aryl
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En sus muchas realizaciones, la presente proporciona compuestos de imidazo [1,2-a]pirazina como inhibidores de quinasas dependientes de ciclina, métodos de preparación de dichos compuestos, composiciones farmacéuticas que contienen uno o más dedichos compuestos, métodos de preparación de formulaciones farmacéuticas que comprenden uno o más de dichos compuestos, y métodos de tratamiento, prevención, inhibición o mejoría de una o más enfermedades asociadas con las CDK, utilizando dichoscompuestos o composiciones farmacéuticas. Reivindicación 1: Un compuesto representado por la fórmula estructural (1) en donde R se selecciona entre el grupo que consiste en alquilo, CF3, heteroarilo, heteroarilalquilo, cicloalquilo,cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilalquilo, -C(O)R7, o como se muestra en los restos de fórmula (2), en donde cada uno de dichos alquilo, heteroarilo, arilalquilo, cicloalquilo, heterociclilo y las porciones heterociclilocuyas estructuras se muestran inmediatamente antes para R pueden estar no sustituidos o en forma opcional, independientemente sustituidos con una o más porciones iguales o diferentes, en donde cada porción se selecciona en forma independiente entreel grupo que consiste en halógeno, alquilo, cicloalquilo, CF3, CN, -OCF3, -OR6, -C(O)R7, NR5R6,-C(O2)R6, -C(O)NR5R6, -(CHR5)nOR6, -SR6, -S(O2)R7, -S(O2)NR5R6, -N(R5)S(O2)R7, -N(R5)C(O)R7 y -N(R5)C(O)NR5R6; R1 es H, halógeno o alquilo; R2 seselecciona entre el grupo que comprende H, halógeno, -CN, cicloalquilo, heterociclilo, alquinilo y -CF3; R3 se selecciona entre el grupo que consiste en arilo (excepto fenilo), heteroarilo (excepto furilo), heterociclilo, -(CHR5)n-heteroarilo, -S(O2)R6, -C(O)R6, -S(O2)NR5R6, -C(O)OR6, -C(O)NR5R6,o como se muestra en los restos de fórmula (3), en donde cada uno de dichos arilo, heteroarilo y heterociclilo pueden estar no sustituidos o en forma opcional sustituidos con una o más porcionesiguales o diferentes, en donde cada porción se selecciona en forma independiente entre el grupo que consiste en halógeno, alquilo, arilo, cicloalquilo, CF3, CN, OCF3, -OR5, -NR5R6, -C(O2)R5, -C(O)NR5R6, -SR6, -S(O2)R6, -S(O2)NR5R6, -N(R5)S(O2)R7, -N(R5)C(O)R7, y -N(R5)C(O)NR5R6; con la condición de que cuando R3 es -(CHR5)n-heteroarilo, R2 adicionalmente puede ser alquilo; R5 es H o alquilo; R6 se selecciona entre el grupo que consiste en H, alquilo, arilo, heteroarilo, arilalquilo, yheteroarilalquilo, en donde cada uno de dichos alquilo, heteroarilalquilo, arilo, heteroarilo y arilalquilo pueden estar no sustituidos o en forma opcional, sustituidos con una o más porciones iguales o diferentes, en donde cada porción seselecciona en forma independiente entre el grupo que consiste en halógeno, alquilo, arilo, cicloalquilo, CF3, OCF3, CN, -OR5, -NR5R6,-CH2OR5, -C(O2)R5, -C(O)NR5R6, -SR6, -S(O2)R7, -S(O2)NR5R6, -N(R5)S(O2)R7, -N(R5)C(O)R7 y -N(R5)C(O)NR5R6; R7 seselecciona entre el grupo que consiste en alquilo, arilo, heteroarilo, arilalquilo y heteroarilalquilo, en donde cada uno de dichos alquilo, heteroarilalquilo, arilo, heteroarilo y arilalquilo pueden estar no sustituidos o en forma opcional,sustituidos con una o más porciones iguales o diferentes, en donde cada porción se selecciona en forma independiente entre el grupo que consiste en halógeno, alquilo, arilo, cicloalquilo, -CF3, -OCF3, -CN, -OR5, -NR5R6, -CH2OR5, -C(O2)R5, -C(O)NR5R6, -SR6, -S(O2)R7, -S(O2)NR5R6, -N(R5)S(O2)R7, -N(R5)C(O)R7 y -N(R5)C(O)NR5R6; R8 se selecciona entre el grupo que consiste en R6, -C(O)NR5R6, -S(O2)NR5R6, -C(O)R7, -C(O2)R6, -S(O2)R7 y -(CH2)-arilo; m es 0 a 4; y n es 1 a 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41290602P | 2002-09-23 | 2002-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR041346A1 true AR041346A1 (es) | 2005-05-11 |
Family
ID=32030939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030103440A AR041346A1 (es) | 2002-09-23 | 2003-09-22 | Derivados de imidazol[1,2-a]pirazinas como inhibidores de quinasas dependientes de ciclinas |
Country Status (13)
Country | Link |
---|---|
US (2) | US7186740B2 (es) |
EP (1) | EP1542693A1 (es) |
JP (1) | JP2006503838A (es) |
KR (1) | KR20060010709A (es) |
CN (1) | CN1694706A (es) |
AR (1) | AR041346A1 (es) |
AU (1) | AU2003275031B2 (es) |
CA (1) | CA2499874A1 (es) |
MX (1) | MXPA05003119A (es) |
NZ (1) | NZ538686A (es) |
TW (1) | TW200412967A (es) |
WO (1) | WO2004026310A1 (es) |
ZA (1) | ZA200502380B (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0977563B1 (en) * | 1996-12-03 | 2005-10-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6919340B2 (en) | 2002-04-19 | 2005-07-19 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP1767535B1 (en) | 2002-08-23 | 2009-12-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
AU2003270489A1 (en) | 2002-09-09 | 2004-03-29 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
DE60317353T2 (de) * | 2002-09-23 | 2008-08-28 | Schering Corp. | Imidazopyrazine als cdk-inhibitoren |
US7576085B2 (en) * | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
US7160885B2 (en) * | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
US20060183746A1 (en) * | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005014599A1 (en) * | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
US7393848B2 (en) * | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005019220A2 (en) * | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
WO2005085252A1 (en) * | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
CN102267978A (zh) * | 2005-01-14 | 2011-12-07 | Cgi药学股份有限公司 | 作为激酶活性调节剂的1,3-二芳基取代的脲 |
US7777040B2 (en) * | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
TW200800213A (en) | 2005-09-02 | 2008-01-01 | Abbott Lab | Novel imidazo based heterocycles |
ATE478852T1 (de) * | 2005-09-09 | 2010-09-15 | Schering Corp | Neue 4-cyano-, 4-amino-, und 4- aminomethylderivative von pyrazoloä1,5- aüpyridinen, pyrazoloä1,5-cüpyrimidinen und 2h- indazolverbindungen und 5-cyano-, 5-amino- und 5- aminomethylderivative von imidazoä1,2-aüpyridinen,und imidazoä1,5-aüpyrazinverbindungen als inhibitoren der cyclinabhänggen kinase |
PE20070435A1 (es) * | 2005-09-16 | 2007-06-13 | Schering Corp | Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasa |
EP1945216A1 (en) * | 2005-11-10 | 2008-07-23 | Schering Corporation | Methods for inhibiting protein kinases |
AU2006315718B2 (en) * | 2005-11-10 | 2012-10-04 | Merck Sharp & Dohme Corp. | Imidazopyrazines as protein kinase inhibitors |
US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
CN103788108B (zh) | 2007-02-06 | 2017-04-12 | 利克斯特生物技术公司 | 氧杂双环庚烷和氧杂双环庚烯,它们的制备及用途 |
EP2185173A4 (en) * | 2007-08-03 | 2011-01-12 | Lixte Biotechnology Inc | USE OF PHOSPHATASES FOR TREATING NEUROBLASTOMES AND MEDULLOBLASTOMES |
AU2008307541B2 (en) | 2007-10-01 | 2015-02-12 | Lixte Biotechnology, Inc. | HDAC inhibitors |
NZ587039A (en) | 2008-02-13 | 2013-01-25 | Gilead Connecticut Inc | 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof |
WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
WO2010014141A1 (en) * | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
AU2009277086B2 (en) | 2008-08-01 | 2015-12-10 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
BRPI0922226A2 (pt) | 2008-12-08 | 2015-12-29 | Gilead Connecticut Inc | inibidores de syk imidazopirazina. |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
TWI478922B (zh) | 2008-12-08 | 2015-04-01 | Gilead Connenticut Inc | 作為脾臟酪胺酸激酶(Syk)抑制劑之咪唑並吡化合物 |
US8993535B2 (en) | 2009-09-04 | 2015-03-31 | Merck Sharp & Dohme Corp. | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
WO2011051342A1 (en) | 2009-10-30 | 2011-05-05 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
EP2545052B1 (en) | 2010-03-11 | 2014-11-12 | Gilead Connecticut, Inc. | Imidazopyridines syk inhibitors |
JP5824065B2 (ja) * | 2010-12-17 | 2015-11-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン |
US20140135319A1 (en) * | 2010-12-17 | 2014-05-15 | Bayer Intellectual Property Gmbh | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
EA027418B1 (ru) | 2011-06-27 | 2017-07-31 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ |
WO2014001314A1 (en) | 2012-06-26 | 2014-01-03 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
BR112015000459B1 (pt) | 2012-07-09 | 2022-02-08 | Janssen Pharmaceutica N.V. | Inibidores da enzima fosfodiesterase 10, seu uso, composição farmacêutica que os compreende, seus processo de preparação e produto |
EA201591931A1 (ru) | 2013-04-09 | 2016-05-31 | Ликсте Байотекнолоджи, Инк. | Композиции оксабициклогептанов и оксабициклогептенов |
PT3027618T (pt) | 2013-07-30 | 2020-10-12 | Kronos Bio Inc | Polimorfo de inibidores de syk |
CA2919522C (en) | 2013-07-30 | 2019-02-26 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
JP6298539B2 (ja) | 2013-12-04 | 2018-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | がんを処置する方法 |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
BR112016028641A2 (pt) | 2014-07-14 | 2017-08-22 | Gilead Sciences Inc | ?método para tratar câncer? |
KR20180083902A (ko) | 2015-11-18 | 2018-07-23 | 젠자임 코포레이션 | 다낭성 신장병의 바이오마커 및 그의 용도 |
KR102399996B1 (ko) | 2017-08-25 | 2022-05-20 | 길리애드 사이언시즈, 인코포레이티드 | Syk 억제제의 다형체 |
WO2020172431A1 (en) | 2019-02-22 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of condensed pyrazines as syk inhibitors |
WO2022061155A1 (en) * | 2020-09-17 | 2022-03-24 | The Translational Genomics Research Institute | Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7 |
CN114042065B (zh) * | 2021-11-26 | 2024-03-15 | 长沙拜特生物科技研究所有限公司 | 一种复方甲苯咪唑透皮溶液剂及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797764A (en) * | 1986-01-27 | 1989-01-10 | Minnesota Mining And Manufacturing Company | Recording disk with low total indicated runout |
FR2607813B1 (fr) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
DK0778277T3 (da) | 1995-12-08 | 2003-10-27 | Pfizer | Substituerede heterocycliske derivater som CRF antagonister |
HUP0301801A2 (hu) | 2000-07-14 | 2003-09-29 | Bristol-Myers Squibb Pharma Company | Imidazo[1,2-a]pirazin-származékok és az ezeket tartalmazó gyógyszerkészítmények |
CZ2003237A3 (cs) | 2000-07-26 | 2003-06-18 | Bristol-Myers Squibb Company | N-(5-{[(5-Alkyl-2-oxazolyl)methyl]thio}-2-thiazolyl) karboxamidy jako inhibitory cyklin-dependentních kináz |
EP1363702A4 (en) * | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | PROCESS FOR INHIBITING KINASES |
US6919340B2 (en) | 2002-04-19 | 2005-07-19 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
DE60317353T2 (de) * | 2002-09-23 | 2008-08-28 | Schering Corp. | Imidazopyrazine als cdk-inhibitoren |
-
2003
- 2003-09-19 WO PCT/US2003/029456 patent/WO2004026310A1/en active Search and Examination
- 2003-09-19 JP JP2004538213A patent/JP2006503838A/ja active Pending
- 2003-09-19 MX MXPA05003119A patent/MXPA05003119A/es active IP Right Grant
- 2003-09-19 US US10/666,424 patent/US7186740B2/en not_active Expired - Fee Related
- 2003-09-19 CN CNA038251027A patent/CN1694706A/zh active Pending
- 2003-09-19 AU AU2003275031A patent/AU2003275031B2/en not_active Ceased
- 2003-09-19 NZ NZ538686A patent/NZ538686A/en unknown
- 2003-09-19 TW TW092125931A patent/TW200412967A/zh unknown
- 2003-09-19 EP EP03759300A patent/EP1542693A1/en not_active Withdrawn
- 2003-09-19 KR KR1020057004674A patent/KR20060010709A/ko not_active Application Discontinuation
- 2003-09-19 CA CA002499874A patent/CA2499874A1/en not_active Abandoned
- 2003-09-22 AR ARP030103440A patent/AR041346A1/es unknown
-
2005
- 2005-03-22 ZA ZA200502380A patent/ZA200502380B/en unknown
-
2007
- 2007-03-01 US US11/680,929 patent/US20070155751A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1694706A (zh) | 2005-11-09 |
US7186740B2 (en) | 2007-03-06 |
CA2499874A1 (en) | 2004-04-01 |
WO2004026310A8 (en) | 2005-06-30 |
US20040072835A1 (en) | 2004-04-15 |
TW200412967A (en) | 2004-08-01 |
ZA200502380B (en) | 2005-09-27 |
NZ538686A (en) | 2008-01-31 |
MXPA05003119A (es) | 2005-06-22 |
JP2006503838A (ja) | 2006-02-02 |
US20070155751A1 (en) | 2007-07-05 |
WO2004026310A1 (en) | 2004-04-01 |
AU2003275031A1 (en) | 2004-04-08 |
AU2003275031B2 (en) | 2006-08-17 |
KR20060010709A (ko) | 2006-02-02 |
EP1542693A1 (en) | 2005-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR041346A1 (es) | Derivados de imidazol[1,2-a]pirazinas como inhibidores de quinasas dependientes de ciclinas | |
AR041347A1 (es) | Derivados de imidazol[1,2-a]pirazinas como inhibidores de quinasas dependientes de ciclinas | |
AR041134A1 (es) | Pirazolopirimidinas como inhibidores de la quinasa dependiente de ciclina | |
AR041133A1 (es) | Pirazolopirimidinas como inhibidores de la quinasa dependientes de la ciclina | |
AR041291A1 (es) | Imidazopiridinas como inhibidores de quinasa dependientes de ciclina | |
CY1122949T1 (el) | ΠΥΡΑΖΟΛΟ[1,5-a]ΠΥΡΑΖΙΝ-4-ΥΛΟ ΠΑΡΑΓΩΓΑ ΩΣ JAK-ΑΝΑΣΤΟΛΕΙΣ | |
EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
ES2564010T3 (es) | Composición farmacéutica para tratar o prevenir el glaucoma | |
PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
RU2007146390A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
AR050952A1 (es) | Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1. | |
PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
NO20053748L (no) | Pyrrolopyridazinderivater. | |
AR063581A1 (es) | Imidazopirazinas como inhibidores de proteina quinasa | |
PE20090556A1 (es) | DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION | |
EA201000947A1 (ru) | Производные тиазола, применимые в качестве ингибиторов киназы pi3 | |
AR029090A1 (es) | Derivados pirazol triciclicos | |
CY1109263T1 (el) | Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine | |
AR041292A1 (es) | Pirazolopiridinas como inhibidores de quinasa dependientes de ciclina | |
AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
EA201171000A1 (ru) | Производные азаспиранилалкилкарбаматов в форме 5-членных гетероциклов, способ их получения и применение в терапии | |
PE20070212A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
DE602006019221D1 (de) | Von dopamin-d3-rezeptoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |